Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera

European Journal of Haematology

Volumn 69, Issue 1, 2002, Pages 43-49

  Jensen, Morten Krogh ^a   Riisbro, Rikke ^b   De Nully Brown, Peter ^a   Brünner, Nils ^b   Hasselbalch, Hans Carl ^a  

^a Rigshospitalet   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

Bone marrow remodeling; Fibrosis; Myeloproliferative disorders; suPAR; uPA

Indexed keywords

GLYCOSYLPHOSPHATIDYLINOSITOL; LACTATE DEHYDROGENASE; METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BONE MARROW; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IDIOPATHIC DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MALIGNANT NEOPLASTIC DISEASE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CELL DIFFERENTIATION; COHORT STUDIES; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MYELOFIBROSIS; POLYCYTHEMIA VERA; RECEPTORS, CELL SURFACE; THROMBOMODULIN; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036659939     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.01732.x     Document Type: Article

References (46)

1. Reilly JT. Pathogenesis of idiopathic myelofibrosis: role of growth factors. J Clin Pathol 1992;45:461-464.
2. Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000;157:15-19.
3. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-1265.
4. Frey BM, Rafii S, Teterson M, Eaton D, Crystal RG, Moore MAS. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol 1998;160:691-699.
5. Martyré MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994;88:9-16.
6. Schmitt A, Jouault H, Guichard J, Wendling F, Drouin A, Cramer EM. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood 2000;96:1342-1347.
7. Rameshwar P, Denny TN, Stein D, Gascón P. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. J Immunol 1994;153:2819-2830.
8. Danø K, Rømer J, Nielsen BS, et al. Cancer invasion and tissue remodeling - cooperation of protease systems and cell types. APMIS 1999;107:120-127.
9. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40.
10. Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
11. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:636-643.
12. Mazzieri R, Masiero L, Zanetta L, et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 1997;16:2319-2332.
13. Murphy G, Gavrilovic J. Proteolysis and cell migration: creating a path. Curr Opin Cell Biol 1999;11:614-621.
14. Cubellis MV, Wun TC, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PA1-1. EMBO J 1990;9:1079-1085.
15. Nykjaer A, Petersen CM, Møller B, et al. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 1992;267:14543-14546.
16. Plesner T, Ralfkiær E, Wittrup M, et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol 1994;102:835-841.
17. Mustjoki S, Alitalo R, Stephens RW, Vaheri A. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: Relationship to classification and response to therapy. Thromb Haemost 1999;81:705-710.
18. Ohtani H, Pyke C, Danø K, Nagura H. Expression of urokinase receptor in various stroma-cell populations in human colon cancer: Immunoelectron microscopical analysis. Int J Cancer 1995;62:691-696.
19. Pyke C, Græm N, Ralfkiær E, et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993;53:1911-1915.
20. Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 1997;15:398-408.
21. Hannocks M-J, Oliver L, Gabrilove JL, Wilson EL. Regulation of proteolytic activity in human bone marrow stromal cells by basic fibroblast growth factor, interleukin-1, and transforming growth factor-beta. Blood 1992;79:1178-1184.
22. Rusbro R, Puronen T, Brünner N, et al. Measurements of soluble urokinase plasminogen activator receptor in serum. J Clin Ligand Assay 2002; in press.
23. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJAG, Høyer-Hansen G, Rønne E. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997;43:1876-1884.
24. Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis. J Natl Cancer Inst 1999;91:869-874.
25. Pyke C, Ralfkiær E, Rønne E, Høyer-Hansen G, Kirkeby L, Danø K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 1994;24:131-138.
26. Slot O, Brünner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: Increased concentrations in rheumatoid arthritis. Ann Rheum Dis 1999;58:488-492.
27. Jensen MK, De Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 2000;110:116-124.
28. Jensen MK, De Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leucocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001;66:143-151.
29. Jensen MK, De Nully Brown P, Thorsen S, Hasselbalch HC. Frequent occurrence of anticardiolipin antibodies, factor V Leiden mutation and perturbed endothelial function in chronic myeloproliferative disorders. Am J Hematol 2002;69:185-191.
30. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols. Semin Hematol 1986;23:132-143.
31. Murphy S, Iland H, Rosenthal D, Laszio J. Essential thrombocythemia: an interim report from the polycythemia vera study group. Semin Hematol 1986;23:177-182.
32. Grøndahl-hansen J, Agerlin N, Munkholm-Larsen P, et al. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Laboratory Clin Med 1988;111:42-51.
33. Chavakis T, Kanse SM, Yutzy B, Lunen R, Preissner KT. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 1998;91:2305-2312.
34. Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol 2000;12:621-628.
35. Wohn K-D, Kanse SM, Deutsch V, Schmidt T, Eldor A, Preissner KT. The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thromb Haemost 1997;77:540-547.
36. Temerinac S, Klippel S, Strunck E, et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia vera. Blood 2000;95:2569-2576.
37. Lund LR, Rømer J, Rønne E, Ellis V, Blasi F, Danø K. Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor-betal in human A549 lung carcinoma cells. EMBO J 1991;10:3399-3407.
38. Falcone DJ, McCaffrey TA, Mathew J, McAdam K, Borth W. THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-beta 1 via increased expression of urokinase and the urokinase receptor. J Cell Physiol 1995;164:334-343.
39. Albo D, Berger DH, Wang TN, Hu X, Rothman V, Tuszynski GP. Thrombospondin-1 and transforming growth factor-beta 1 promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. Surgery 1997;122:493-500.
40. Shetty S, Kumar A, Johnson AR, et al. Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs. Am J Respir Cell Mol Biol 1996;15:78-87.
41. Zhang LP, Takahara T, Yata Y, et al. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. J Hepatol 1999;31:703-711.
42. Lardot CG, Huaux FA, Broeckaert FR, et al. Role of urokinase in the fibrogenic response of the lung to mineral particles. Am J Respir Crit Care Med 1998;157:617-628.
43. Odekon LE, Blasi F, Rifkin DB. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-B to TGF-B. J Cell Physiol 1994;158:398-407.
44. Hildenbrand R, Jansen C, Wolf G, et al. Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast. Laboratory Invest 1998;78:59-71.
45. De Witte H, Sweep F, Brünner N, et al. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay. Int J Cancer 1998;77:236-242.
46. Grøndahl-Hansen J, Ralfkiær E, Kirkeby LT, Kristensen P, Lund LR, Danø K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinoma of the colon in humans. Am J Pathol 1991;138:111-117.